Vociprotafib clinical trials
Also written RMC-4630 and SAR442720.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses vociprotafib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Revolution Medicines, Inc. (2) · Amgen (1) · Sanofi (1) · The Netherlands Cancer Institute (1)
Often tested with
Tested in the same studies.
Sotorasib (1) · Batoprotafib (1) · Pan-KRAS Inhibitor BI 1701963 (1) · Zeluvalimab (1) · LY3214996 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test vociprotafib.
Studies
Open first, then newest update. How each study uses vociprotafib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesCompletedPhase 2Revolution Medicines, Inc.NCT05054725Written as RMC-4630How we know
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingPhase 1AmgenNCT04185883Written as RMC-4630How we know
- Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced MalignanciesTerminatedPhase 1/2SanofiNCT04418661Written as VociprotafibHow we know
- Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant CancersTerminatedPhase 1The Netherlands Cancer InstituteNCT04916236Written as RMC-4630How we know
- Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsStatus unknownPhase 1Revolution Medicines, Inc.NCT03634982Written as RMC-4630How we know
Given beside what is tested · 1 — vociprotafib is usual care or a partner of the new treatment
Codes
What other systems call vociprotafib · ClinicalTrials.gg INT016178
- UNII (FDA) C4YBF9170LVOCIPROTAFIBOne source FDA
- NCI Thesaurus C155850VociprotafibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C4YBF9170L | VOCIPROTAFIB | One source FDA |
| NCI Thesaurus | C155850 | Vociprotafib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.